Minerva Neurosciences raises up to $200M to fund Phase 3 trial of roluperidone

Minerva Neurosciences, Inc.

Private placement: $80M upfront Series A preferred; Tranche A warrants for another $80M (cash exercise), Tranche B warrants for $40M contingent on milestone event.
Proceeds to finance Phase 3 confirmatory trial, NDA resubmission, and U.S. commercial launch readiness for roluperidone in negative symptoms of schizophrenia.
Board to increase by up to three directors designated by Vivo Capital, expected to have schizophrenia trial experience.
Closing expected October 23, 2025; led by Vivo Capital with participation from Janus Henderson, Farallon, and others.
Company notes alignment with FDA on confirmatory trial design announced August 2025.

item 1.01 item 3.02 item 5.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Minerva Neurosciences, Inc. issued tranche A warrants to acquire shares of Series A Preferred Stock and tranche B warrants to acquire shares of Series A Preferred Stock of warrant to certain accredited investors for Exercise price $1,000 per share, aggregate cash exercise price up to $80 million for Tranche A and $40 million for Tranche B.

Security: warrant
Shares: tranche A warrants to acquire shares of Series A Preferred Stock and tranche B warrants to acquire shares of Series A Preferred Stock
Purchaser: certain accredited investors
Consideration: Exercise price $1,000 per share, aggregate cash exercise price up to $80 million for Tranche A and $40 million for Tranche B

Exact text from the filing

placement (the “Private Placement”), (i) 80,000 shares of Series A Convertible Preferred Stock, par value $0.0001 per share (“Series A Preferred Stock”), at a purchase price of $1,000 per share, (ii) tranche A warrants (the “Preferred Tranche A Warrants”) to acquire shares of Series A Preferred Stock (the “Tranche A Warrant Shares”) and (iii) tranche B warrants

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Minerva Neurosciences, Inc. issued 80,000 shares of Series A Convertible Preferred Stock of preferred stock to certain accredited investors for $1,000 per share.

Security: preferred stock
Shares: 80,000 shares of Series A Convertible Preferred Stock
Purchaser: certain accredited investors
Consideration: $1,000 per share

Exact text from the filing

The Company agreed to issue and sell, in a private placement (the “Private Placement”), (i) 80,000 shares of Series A Convertible Preferred Stock, par value $0.0001 per share (“Series A Preferred Stock”), at a purchase price of $1,000 per share

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 1.0

Minerva Neurosciences, Inc.: The Company filed a Certificate of Designation designating 200,000 shares of authorized preferred stock as Series A Convertible Voting Preferred Stock (effective 2025-10-21).

Change: charter amendment
Effective: 2025-10-21

Exact text from the filing

on October 21, 2025, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware, designating 200,000 shares of its authorized and unissued preferred stock as Series A Preferred Stock

View on SEC.gov

173 equity issuances filed in the last 30 days. Browse all equity issuances →

Minerva Neurosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-245552

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.